2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Element Solutions and Solstice Advanced Materials agreed on August 27, 2026 to terminate the merger agreement they signed on July 6, 2026. Under the termination agreement, neither company owes the other a payment, and the parties mutually release each other from related liability claims, subject to customary exceptions. The company said both boards concluded the two companies would serve shareholders better as standalone companies.
Merger agreement with Solstice Advanced Materials Inc. dated July 6, 2026, now terminated
Termination Agreement signed August 27, 2026 by Element Solutions, Solstice and the two Merger Subs
Neither party will make termination payments to the other; mutual release of liability claims, subject to customary exceptions
CEO Benjamin Gliklich said the company's momentum continues in line with its guidance
JBG SMITH Properties LP entered into a Second Amended and Restated Credit Agreement with Bank of America on August 27, 2026, providing a $690.0 million senior unsecured revolver maturing August 27, 2030, with $230.0 million drawn as of that date. The company also amended two Wells Fargo term loans and its $120.0 million 2023 Term Loan to align covenants with the new revolver, extending part of a $400.0 million term loan to August 25, 2028.
$690.0 million revolving facility replaces the $750.0 million Existing Credit Agreement, which was due June 29, 2027; $230.0 million was drawn as of August 27, 2026
Revolver matures August 27, 2030, with two six-month extension options at a 0.075% fee each
$228.9 million of the $400.0 million Tranche A-2 term loan was extended to August 25, 2028; $171.1 million remains due January 13, 2028, and the term loan was increased by $15.0 million
Financial covenants include total indebtedness to property valuation of not more than 60% and EBITDA to fixed charges of at least 1.50 to 1.00
Southern First Bancshares' Board authorized a share repurchase plan of up to $10.0 million of common stock, roughly 2% of the company's shares. The company may buy back shares through open market and privately negotiated transactions, with timing and amounts at management's discretion, and the company is not obligated to repurchase any shares.
Authorized repurchase of up to $10.0 million of common stock, or approximately 2%
Purchases may be made in open market and privately negotiated transactions, at management's discretion
Repurchases after August 23, 2027 would require additional Board and Federal Reserve approval
Plan may be discontinued, suspended or restarted at any time
BitGo entered into a merger agreement to acquire the institutional trading business of NYDIG, through a two-step merger with NYDIG IF Holdings LLC. Consideration includes $7,000,000 in cash, shares valued at about $35,500,000 at closing, and contingent cash and share payments tied to revenue milestones.
Closing consideration: $7,000,000 cash plus shares with an aggregate value of approximately $35,500,000
Contingent payments: $10,000,000 cash on a first revenue milestone, and up to $5,000,000 cash plus additional shares on a second milestone
Approximately 30 NYDIG employees are expected to join BitGo, along with institutional client trading relationships
BitGo agreed to file a registration statement covering the shares within 180 days after closing or 5 days after becoming S-3 eligible, whichever is earlier
Koss Corporation reported fourth-quarter fiscal 2026 net sales of $3,263,853, up 5.8%, and net income of $476,801, compared with a net loss of $232,696 a year earlier. For the full year, sales rose 3.1% to $13,020,773 and the net loss narrowed to $391,464 from $874,831, with $1.0 million of tariff refunds received in the fourth quarter helping gross margin improve to 41.9%. Both headline sales and profit measures improved for shareholders, although the filing gives no forward guidance and European distributor sales declined.
Q4 net sales were $3,263,853, up $179,643 or 5.8% from $3,084,210 a year earlier.
Q4 net income was $476,801, or $0.05 per share, versus a net loss of $232,696, or $0.02 per share, in the prior-year quarter.
Full-year net loss was $391,464, or $0.04 per share, down $483,367 from $874,831, or $0.09 per share, in fiscal 2025.
Full-year gross margin rose to 41.9% from 37.8%, helped by $1.0 million in tariff refunds received in the fourth quarter.
Solstice Advanced Materials and Element Solutions mutually terminated their July 6, 2026 merger agreement on August 27, 2026, and neither party owes the other a payment. Solstice's board also approved a share repurchase program of up to $500 million, and the company reaffirmed its 2026 guidance.
Merger Agreement signed July 6, 2026 was terminated by mutual agreement; no termination fees are payable by either party.
Board authorized repurchases of up to $500 million of common stock, to be funded with cash on hand and cash from operations.
Goldman Sachs commitment letter and the Sir Martin E. Franklin voting and support agreement terminated automatically.
Full-year 2026 guidance affirmed: net sales of $4.125 billion to $4.185 billion and adjusted EBITDA of $1.035 billion to $1.055 billion.
Alto Neuroscience promoted Chief Financial Officer and Chief Business Officer Nicholas C. Smith to President and Chief Financial Officer effective August 26, 2026. CEO Amit Etkin remains chief executive but no longer holds the title of President. Smith's promotion comes with a $6 million cash retention agreement, which he forfeits if he leaves or is terminated for Cause before the two-year anniversary.
Nicholas C. Smith named President and Chief Financial Officer, effective August 26, 2026
Amit Etkin, M.D., Ph.D. continues as Chief Executive Officer and is no longer President
Retention Payment totals $6,000,000: $3,000,000 within ten days of the Effective Date and $3,000,000 at the twelve-month anniversary
Unpaid portion is forfeited and paid amounts may be recouped if Smith leaves before the two-year anniversary
Southland's subsidiaries agreed on August 26, 2026 to pay Liberty Mutual $5 million by September 30, 2026 to resolve about $36.4 million of surety losses tied to the Washington State Convention Center project. Southland expects the settlement to favorably affect pre-tax income by about $29 million in the third quarter of 2026, though that estimate is preliminary and subject to accounting review.
Settlement with Liberty Mutual, Zurich American and Fidelity and Deposit covers about $36.4 million of surety losses, about $34 million of which relates to the WSCC Judgement.
Company will pay $5 million to Liberty on or before September 30, 2026.
Preliminary estimate: favorable impact of about $29 million on income before income taxes in Q3 2026, subject to change.
Negotiations with Zurich to resolve the remaining surety payable related to the WSCC Judgement are ongoing.
Satellogic appointed Dustin Greer, its Senior Vice President and Corporate Controller since 2022, as Interim Chief Financial Officer, effective immediately, and he will also serve as principal accounting officer. The filing does not state why the prior CFO role changed, and it reports no new compensation arrangement with Mr. Greer tied to the appointment.
Dustin Greer appointed Interim CFO effective August 21, 2026, and also serves as principal accounting officer
Greer, age 47, has been Senior Vice President and Corporate Controller since 2022
Filing states no material plan, contract or arrangement was entered into or amended in connection with the appointment
Concentra Group Holdings Parent agreed on August 21, 2026 to buy 1,000,000 shares of its common stock from chairman Robert A. Ortenzio and related entities in a privately negotiated deal, closing August 24, 2026. The purchase, funded with cash on hand and approved by the independent Audit and Compliance Committee, represents about 0.784% of shares outstanding and reduces the share count shareholders own a stake in.
1,000,000 shares purchased at $34.65 per share, for a total of $34.65 million
Price is a 1% discount to the August 21, 2026 closing price
Transaction closed August 24, 2026; funded through cash on hand
Stockholders said the sale is to diversify their investment portfolios for financial planning purposes
JetBlue disclosed that directors Jesse Lynn and Steven D. Miller resigned from its board, effective August 24, 2026, after the Icahn Group's ownership fell below the level that entitled it to two board seats under a 2024 agreement. The filing says the resignations were not due to any disagreement with the company's operations, policies or practices.
Resignations effective August 24, 2026, following notice from the Icahn Group on August 21, 2026
Jesse Lynn also left the audit, governance and nominating, and finance committees
Steven D. Miller also left the audit and finance committees
Resignations were tied to the Director Appointment and Nomination Agreement dated February 16, 2024
Affirm Holdings furnished a shareholder letter on its fourth fiscal quarter ended June 30, 2026 results, which is attached as Exhibit 99.1. The Board also appointed Michael Linford as President, effective August 27, 2026, with expanded oversight of legal, compliance, public affairs, revenue and global markets functions, and his compensation was unchanged.
Shareholder letter dated August 27, 2026 covers the fiscal fourth quarter ended June 30, 2026; it includes non-GAAP measures reconciled in the letter.
Board appointed Michael Linford as President on August 25, 2026, effective August 27, 2026; he was COO from September 2024 and CFO from August 2018 to November 2024.
Libor Michalek remains President, overseeing engineering, risk, operations, product and design; Linford and Michalek report to CEO Max Levchin.
Gap reported second-quarter fiscal 2026 net sales of $3.7 billion, down 2% from a year earlier, while GAAP diluted earnings per share rose to $1.38 from $0.57, helped by a $417 million tariff recovery adjustment. The company raised its adjusted full-year EPS outlook to $2.35 to $2.45 but narrowed its net sales growth outlook to up 1% to 1.5%, and said Old Navy CEO Horacio Barbeito will step down effective November 2, 2026, with Michael Francis succeeding him.
Net sales were $3.7 billion, down 2%; comparable sales fell 1%, with Old Navy down 4% and Gap up 10%.
GAAP diluted EPS was $1.38 versus $0.57 a year earlier; adjusted diluted EPS, excluding the net tariff recovery, was $0.52.
Fiscal 2026 adjusted diluted EPS outlook raised to $2.35 to $2.45 from $2.30 to $2.40; net sales outlook is up 1% to 1.5%, down from up 1% to 2%.
Horacio Barbeito steps down as Old Navy President and CEO effective November 2, 2026; Michael Francis, Chief Customer Officer, takes over that day.
Southern Cross Acquisition II Corp., a blank check company, closed its initial public offering on August 27, 2026, selling 7,652,630 units at $10.00 each for gross proceeds of $76,526,300. About $76,717,616 from the IPO and private unit sale was placed in a trust account, and access to those funds is restricted until a business combination or other specified events occur. The company also appointed three independent directors and adopted amended and restated articles of association.
Closed IPO on August 27, 2026 of 7,652,630 units at $10.00 per unit, including a partial over-allotment of 152,630 units, for gross proceeds of $76,526,300.
Sold 224,932 private units to the Sponsor and D. Boral Capital LLC for $2,249,320.
About $76,717,616 placed in the trust account; funds are not released until a business combination, a shareholder redemption event, or failure to complete a business combination within 12 months.
Hongmei Zhao, Wenhua Qian and Zhiqiang Du became independent directors effective August 26, 2026.
GE Vernova said CFO Kenneth Parks will retire on April 2, 2027, and that Claire McDonough, currently CFO of Rivian Automotive, will become CFO effective January 1, 2027. McDonough joins as a strategic advisor on November 1, 2026, ahead of taking the role, which is a planned succession that shareholders may watch for continuity in financial leadership.
Kenneth Parks, CFO, will retire on April 2, 2027, and serve as strategic advisor to CEO Scott Strazik from January 1, 2027 until then.
Claire McDonough, 45, becomes CFO effective January 1, 2027; she joins as strategic advisor on November 1, 2026.
McDonough's offer includes $1,000,000 base salary, a 100% target annual incentive, a $5,225,000 target LTIP grant expected in 2027, a $14,500,000 make-whole LTIP award, and a $5,000,000 cash sign-on payment.
The filing says full agreements will be filed with the Form 10-Q for the quarter ending September 30, 2026.
Devon Energy's Compensation Committee approved a higher base salary and a new restricted stock award for CEO and President Clay M. Gaspar. The salary increase is retroactive to May 7, 2026, the closing date of the Coterra Energy merger, and the stock award is valued at $2.7 million. The filing reports compensation changes only and gives no financial results, so it does not indicate operating performance.
Base salary raised to an annualized rate of $1,500,000, effective retroactively to May 7, 2026
Restricted stock award valued at $2,700,000, based on the closing price on the September 10, 2026 grant date
Stock award vests in three annual installments from the grant date
Committee approved the changes on August 21, 2026, citing benchmarking data and its consultant's recommendation
Avidbank Holdings sold $30 million of 7.00% fixed-to-floating subordinated notes due September 1, 2036, under an agreement dated August 26, 2026, with institutional purchasers. The company plans to use the proceeds to redeem its $22 million of 5.000% subordinated notes due 2029 and for general corporate purposes, and on August 27, 2026 it repurchased $18 million of those 2029 notes and called the remaining $4 million for September 30, 2026.
$30 million of notes sold at 100% of face amount, fixed at 7.00% until September 1, 2031, then resetting quarterly to three-month term SOFR plus 291 basis points
On August 27, 2026, $18 million of the 2029 notes were repurchased for about $18.2 million, including accrued interest; the remaining $4 million is to be redeemed on September 30, 2026
The notes are unsecured, subordinated obligations, are intended to qualify as Tier 2 regulatory capital, and were sold in a private placement with Piper Sandler & Co. as sole placement agent
IREN reported fiscal 2026 revenue of $707.0 million, up from $501.0 million a year earlier, with AI Cloud Services revenue rising to $128.8 million from $16.4 million. The company swung to a net loss of $702.6 million from net income of $86.9 million, largely due to non-cash asset impairments tied to converting Bitcoin mining sites for AI Cloud use. The filing also announced a new multi-year AI Cloud contract with a leading frontier AI lab, which matters to shareholders because it signals demand for the company's capacity, though the stated $4 billion contracted ARR target is an internal operating metric rather than GAAP revenue.
FY26 total revenue was $707.0 million versus $501.0 million in FY25; AI Cloud Services revenue was $128.8 million versus $16.4 million.
FY26 net loss was $702.6 million versus net income of $86.9 million in FY25; impairments were $638.8 million for the year.
Q4 FY26 net loss was $684.0 million, including $450.4 million of impairments; Q4 adjusted EBITDA was $19.2 million versus $59.5 million in the prior quarter.
As of August 26, 2026, operating ARR was $1 billion, with $4 billion of contracted ARR for 2026 capacity.
Outlook Therapeutics said its CFO Lawrence A. Kenyon will leave the role effective September 1, 2026, and the Board appointed Kevin Lundquist as CFO, Treasurer and principal financial and accounting officer from the same date. Kenyon will stay on in a non-executive role through September 30, 2026, and will step down from the Board, which will shrink to eight directors. The company says the departure was not due to any disagreement over accounting, financial reporting or operations.
Kevin Lundquist, 58, was CFO of CapsoVision Inc. from October 2024 to February 2026 and previously was CFO of Abzena Biologics from 2022 to 2023.
Lundquist's base salary is $450,000, with a target bonus of 50% of salary and an option to buy 500,000 shares.
Kenyon's separation agreement provides a lump sum of 12 months' base salary, $20,000 and his full 2026 target bonus, plus full option vesting and up to 12 months of COBRA benefits.
Titan Acquisition Corp. filed an August 2026 investor presentation with OpenPayd for use in meetings with existing and potential shareholders about their proposed business combination. The deck reports $96 million in annual recurring revenue (ARR) and more than $300 billion in annualized transaction volume as of July 31, 2026, and says a Nasdaq listing is anticipated by calendar Q4 2026. The filing is furnished rather than filed and does not contain new audited financial results.
ARR of $96 million as of July 31, 2026; the deck defines ARR as one month's revenue multiplied by twelve and says it is not a forecast
Annualized transaction volume of $300 billion or more as of July 2026, with more than 1,200 clients
Presentation information is current as of August 26, 2026; a Nasdaq listing is anticipated by calendar Q4 2026
The deck says the business combination remains subject to shareholder approval, closing conditions and possible changes to terms
SentinelOne reported second-quarter fiscal 2027 revenue of $292 million, up 21% from a year earlier, and said it exceeded its guidance. The company raised its fiscal 2027 revenue and non-GAAP operating income outlook, but it still reported a GAAP net loss of $93.4 million for the quarter.
Q2 revenue was $292 million, up from $242 million; annualized recurring revenue (ARR) grew 22% to $1.218 billion as of July 31, 2026.
Fiscal 2027 revenue guidance is now $1.202 billion to $1.207 billion; non-GAAP operating income guidance is $124 million to $128 million.
GAAP net loss was $93.4 million, or $(0.27) per share, versus $(0.22) a year earlier; non-GAAP diluted EPS was $0.08, versus $0.04.
Cash, cash equivalents and investments totaled $813 million as of July 31, 2026.
Ulta Beauty reported second-quarter fiscal 2026 results with net sales up 8.9% to $3.0 billion and diluted EPS up 13.3% to $6.55. The company raised its fiscal 2026 diluted EPS outlook to $28.70 to $29.00 from $28.36 to $28.80 and increased its fiscal 2026 stock repurchase plan to $1.8 billion from $1.5 billion, which matters to shareholders because it signals stronger expected profit and more capital returned to them.
Net sales rose 8.9% to $3.0 billion, while comparable sales increased 3.8% for the quarter ended August 1, 2026.
Operating income increased 10.1% to $379.6 million; gross margin slipped to 39.1% from 39.2%.
Updated fiscal 2026 diluted EPS outlook is $28.70 to $29.00, up from $28.36 to $28.80.
Fiscal 2026 repurchase plan increased to $1.8 billion from $1.5 billion; $1.0 billion remained under the $3.0 billion program as of August 1, 2026.
Elastic reported first-quarter fiscal 2027 results for the quarter ended July 31, 2026, with total revenue of $478 million, up 15% year over year. GAAP net loss narrowed to $16.7 million from $24.6 million a year earlier, and non-GAAP diluted earnings per share rose to $0.70 from $0.60. The company also issued guidance for the second quarter and full fiscal 2027, with fiscal 2027 revenue expected between $1.998 billion and $2.010 billion.
Total revenue of $478 million, up 15% year over year; sales-led subscription revenue of $399 million, up 18%
GAAP net loss of $16.7 million versus $24.6 million a year earlier, including a $19.9 million restructuring and other related charge
Non-GAAP diluted earnings per share of $0.70 versus $0.60 a year earlier
Q2 fiscal 2027 revenue guidance of $486 million to $487 million; fiscal 2027 revenue guidance of $1.998 billion to $2.010 billion
PagerDuty reported second-quarter fiscal 2027 revenue of $124.4 million, up 0.8% year over year, with GAAP net income attributable to common stockholders of $4.7 million, or $0.06 per diluted share, down from $9.8 million, or $0.10, a year earlier. The company also said it is reducing current headcount by approximately 15%, with estimated non-recurring charges of $5.5 million to $7.5 million, mostly in the third quarter of fiscal 2027, which matters to shareholders because it adds costs while the company reports slower profit growth.
Revenue was $124.4 million, up 0.8% year over year; GAAP operating income was $10.2 million versus $3.6 million a year earlier.
Net income attributable to common stockholders was $4.7 million ($0.06 diluted per share), compared with $9.8 million ($0.10) in the prior-year quarter.
Headcount reduction of approximately 15%; estimated charges of $5.5 million to $7.5 million, mostly in Q3 fiscal 2027, with implementation substantially complete by end of Q4 fiscal 2027.
Full fiscal 2027 revenue outlook is $491.5 million to $496.5 million; non-GAAP operating margin outlook is 25.0% to 26.0%.
On August 21, 2026, Rocket Pharmaceuticals adopted a company-wide Severance and Change in Control Program and entered into employment agreements or an amendment with its CEO, General Counsel and Chief Operating Officer. The filing sets out severance levels, including enhanced payments if a termination occurs around a change in control, which define the company's potential payout obligations to these executives.
Program adopted August 21, 2026; CEO receives 15 months base salary without a change in control and 18 months within 12 months after one
CEO Gaurav Shah's agreement sets an annual base salary of $674,856 and a 60% target bonus
General Counsel Martin Wilson's agreement sets an annual base salary of $547,313 and a 45% target bonus
Chief Operating Officer Christopher Stevens' amendment, dated August 21, 2026, amends his July 7, 2025 agreement
Rubrik reported second-quarter fiscal 2027 revenue of $427.3 million, up 38% from a year earlier, and a GAAP net loss of $(0.30) per share, narrower than $(0.49) a year earlier. The company raised guidance for all guided metrics for fiscal 2027 and said results exceeded all guided metrics. The board also added Rakefet Russak-Aminoach as a director, expanding the board from eight to nine members.
Q2 total revenue $427.3 million, up 38% from $309.9 million; subscription ARR $1.66 billion, up 33% year over year
GAAP net loss per share $(0.30) vs $(0.49); non-GAAP diluted net income per share $0.20 vs $(0.03)
Fiscal 2027 revenue guidance $1,685 million to $1,693 million; free cash flow guidance $323 million to $333 million
Rakefet Russak-Aminoach appointed Class I director effective August 26, 2026, with a term expiring at the 2028 annual meeting
LifeVantage reported fourth-quarter and full fiscal 2026 results (year ended June 30, 2026) showing sharp declines in revenue and profit from the prior year. The company is not issuing formal fiscal 2027 guidance because of the recent transition in its Chief Executive Officer role, leaving shareholders without a company forecast for the coming year.
Fiscal 2026 revenue was $182.6 million, down 20.1% from $228.5 million in fiscal 2025; Americas revenue fell 23.2%.
Fourth-quarter revenue was $42.4 million, down 23.1%, and diluted EPS was $0.10 versus $0.15 a year earlier.
Fiscal 2026 diluted EPS was $0.40 versus $0.75; adjusted EPS was $0.56 versus $0.82.
No formal fiscal 2027 guidance was issued due to the recent CEO transition; Terrence Moorehead is President and CEO.
Marvell reported record second-quarter fiscal 2027 net revenue of $2.739 billion, up 37% from a year earlier and $39.0 million above the midpoint of its May 27, 2026 guidance. GAAP net income was $308.0 million, or $0.33 per diluted share, compared with $194.8 million, or $0.22, a year earlier. The company said it is again raising its revenue outlook for fiscal 2027 and fiscal 2028, and it expects third-quarter revenue of $3.150 billion, plus or minus 5%.
Data center revenue was $2.171 billion, up 46% year over year, while communications and other revenue was $567.8 million, up 10%.
Q2 non-GAAP diluted EPS was $0.94, compared with $0.67 a year earlier; GAAP diluted EPS was $0.33.
Third-quarter outlook: net revenue of $3.150 billion plus or minus 5%, and non-GAAP diluted EPS of $1.10 plus or minus $0.05.
Marvell will hold an Investor Day on October 6, 2026.
Rein Therapeutics received a Nasdaq notice on August 21, 2026, because its common stock closed below $1.00 per share over the previous 30 consecutive trading days. The company has until February 17, 2027 to regain compliance, and Nasdaq says it will start suspension and delisting procedures if compliance is not regained in time.
Notice received from Nasdaq on August 21, 2026 under Rule 5550(a)(1), the minimum $1.00 bid price standard
Compliance deadline is February 17, 2027, 180 days from the notice date
Regaining compliance requires a closing bid price of at least $1.00 for a minimum of 10 consecutive business days
Filing states there is no assurance of additional time after the initial 180-day period
Autodesk reported second-quarter fiscal 2027 revenue of $2.05 billion, up 16% year over year, and GAAP diluted earnings per share of $2.33 versus $1.46 a year earlier. The company raised its fiscal 2027 billings and revenue growth guidance, citing higher underlying growth expectations and the contribution from the MaintainX acquisition, while keeping its non-GAAP operating margin guidance unchanged.
Q2 revenue of $2,046 million, up 16% (14% in constant currency); billings of $1,854 million, up 10%
GAAP diluted EPS of $2.33 versus $1.46 a year earlier; non-GAAP EPS of $3.30, up $0.68 year over year
FY27 revenue guidance of $8,295 million to $8,345 million; non-GAAP operating margin guidance unchanged at about 39%
FY27 free cash flow guidance narrowed to $2,725 million to $2,750 million, including about $45 million of MaintainX transaction expenses
Alerus Financial declared a quarterly cash dividend of $0.22 per share, a 4.76% increase over the dividend paid a year earlier, payable October 9, 2026 to holders of record on September 25, 2026. The board also approved a new stock repurchase program for up to 1,250,000 shares, which takes effect once the prior program's remaining authorization is used up or the prior program ends, and runs through August 26, 2029. The company is not obligated to buy any shares under the new program.
Quarterly dividend of $0.22 per share, payable October 9, 2026 to holders of record September 25, 2026
Dividend is 4.76% above the amount paid a year ago
New repurchase program authorizes up to 1,250,000 shares and expires August 26, 2029
About 320,033 shares remained under the prior program as of August 26, 2026; the prior program is scheduled to expire February 18, 2027
Sun Communities entered into an amended and restated employment agreement with Chief Investment Officer and Executive Vice President Aaron Weiss, dated August 21, 2026, which takes effect October 19, 2026. The filing sets a $600,000 base salary, a 100% target bonus and enhanced severance and change-in-control terms, which shareholders may view as relevant to executive pay costs and retention.
Base salary of $600,000 with an annual cash bonus target of 100% of base salary
Five-year term beginning October 19, 2026, with automatic one-year renewals
Severance on termination without cause or for good reason equals 1.5 times base salary plus target bonus; change-in-control payment equals two times base salary plus target bonus
Workday reported fiscal 2027 second-quarter total revenues of $2.649 billion, up 12.8% year over year, and non-GAAP diluted earnings per share of $2.75, up from $2.21. The company raised its fiscal 2027 non-GAAP operating margin guidance to 31.0% and authorized an open-ended repurchase of up to $4.0 billion of Class A common stock.
Total revenues of $2.649 billion, up 12.8%; subscription revenues of $2.471 billion, up 13.9%
GAAP diluted net income per share of $2.57 includes a $1.52 per share tax benefit tied to an intellectual property transfer; non-GAAP figure was $2.75
Fiscal 2027 subscription revenue guidance of $9.940 billion to $9.950 billion; non-GAAP operating margin guidance raised to 31.0%
Operating cash flow was $520 million versus $616 million a year earlier; free cash flow was $460 million versus $588 million
Key Tronic reported fiscal fourth-quarter 2026 revenue of $102.0 million, up 14% from $89.6 million in the prior quarter but down from $110.5 million a year earlier. The net loss widened to $34.3 million, or $3.16 per share, from $3.9 million a year earlier, mainly because of a $28.4 million non-cash deferred tax valuation allowance charge. The company will not issue revenue or earnings guidance for the first quarter of fiscal 2027, and the results remain preliminary pending the auditor's completion of its procedures.
Q4 revenue was $102.0 million, up 14% from $89.6 million in the prior quarter and down from $110.5 million a year earlier.
Q4 net loss was $34.3 million ($3.16 per share), versus $3.9 million ($0.36 per share) a year earlier, including a $28.4 million non-cash tax charge.
Q4 adjusted net loss narrowed to $2.9 million ($0.26 per diluted share) from $3.8 million ($0.35) a year earlier.
No revenue or earnings guidance for Q1 fiscal 2027; the financial data is preliminary and subject to change pending the independent audit.
A federal court in Nevada dismissed all claims the SEC brought against Live Ventures in its 2021 enforcement action, with no judgment, penalty, admission or findings against the company. CEO Jon Isaac separately agreed to a consent judgment with a $175,000 civil penalty on the individual claims against him, while denying the allegations.
Court dismissed all claims against Live Ventures in the SEC civil action, Case No. 2:21-cv-01433-JCM-MDC, filed August 2021
Company faced no judgment, penalty, admission or findings of any kind
Jon Isaac agreed to a consent judgment with a $175,000 civil penalty; he admits no wrongdoing and denies the allegations
NeuroOne Medical Technologies announced that three large-animal procedures using its StereoCED platform were completed at the University of Minnesota as part of a preclinical epilepsy research program. The company says the procedures established technical feasibility, and it expects to recognize related animal-use revenue in fiscal Q4 2026 and plans a launch for human investigational studies later this quarter, though the filing gives no revenue amount and the platform is not approved for commercial use.
Three large-animal procedures completed at the University of Minnesota, announced August 27, 2026
In two of the three procedures, drug delivery electrodes delivered a study agent into targeted brain tissue and recorded electrophysiological activity from the same regions
Revenue from the animal-use devices is expected to be recognized in fiscal Q4 2026; no dollar amount is given
Human investigational device release is planned by the end of fiscal Q4 2026, with launch planned later this quarter
Onfolio Holdings said Nasdaq has determined it regained compliance with the $1.00 minimum bid price rule, and Nasdaq considers the matter closed. The company received the original notice on July 2, 2026, and its closing bid price stayed at or above $1.00 from August 10 to August 25, 2026. The filing shows the company is no longer at risk of a Nasdaq listing action over this issue, but it does not give financial results.
Nasdaq notice on July 2, 2026 said the stock had failed to maintain a minimum bid price of $1.00 for 30 consecutive business days.
Closing bid price was at or above $1.00 for 12 consecutive business days, from August 10 to August 25, 2026.
Press release dated August 27, 2026 (Exhibit 99.1) announced the regained compliance under Nasdaq Listing Rule 5550(a)(2).
CEO Dominic Wells said the reverse split was enacted about two weeks before the release to restore compliance.
Dolby Laboratories appointed Marc Whitten as President, Chief Executive Officer and a board member, effective August 27, 2026, succeeding Kevin Yeaman, who retired from those roles on the same date. Yeaman will provide consulting services through the end of calendar 2027, and the filing describes Whitten's pay package, which includes a $1,000,000 base salary, a $2,100,000 sign-on bonus and performance-based equity tied to stock-price hurdles.
Whitten's annual salary is $1,000,000, with a target bonus of 100% of base salary beginning in fiscal 2027.
Whitten receives a $2,100,000 sign-on bonus, subject to prorated repayment if he leaves within 24 months, other than for Good Reason or Cause.
Whitten's new hire awards include a 600,000-unit performance-based RSU award with stock-price hurdles from $75 to $175.
Yeaman will receive $40,000 per month for six months as a consultant and his outstanding equity awards will continue to vest.
Vince Holding's subsidiary completed the acquisition of the operating business of October's Very Own (OVO), a Canadian streetwear lifestyle brand, on August 24, 2026, while Authentic Brands Group took majority ownership of OVO's intellectual property. The company will hold a 5% stake in the OVO IP for $6,000,000 and a license to use it, with royalties payable to Authentic, and says the deal is expected to be earnings neutral in fiscal 2026 and accretive in fiscal 2027. The company also expects second quarter fiscal 2026 results at the high end of its prior guidance, excluding any tariff refund benefit.
OVO operating business acquired; the purchase agreement closed on August 24, 2026
Company to own 5% of OVO IP for $6,000,000 and hold a license with an initial term ending at the end of fiscal 2036
Q2 fiscal 2026 results expected at the high end of prior guidance, excluding any benefit from tariff refunds
Full second quarter results to be reported by September 15, 2026
MBX Biosciences said it has dosed the first patient in its pivotal Phase 3 oPTimize trial of once-weekly canvuparatide for chronic hypoparathyroidism. The trial is planned to enroll approximately 160 adults and is a step toward potential registration of the drug candidate, though the filing reports no financial results or regulatory approval.
First patient dosed in the Phase 3 oPTimize trial, announced August 27, 2026
Trial plans to enroll approximately 160 adults, randomized 3:1 to canvuparatide or placebo over a 26-week double-blind period
Primary endpoint is a composite responder measure at Week 26, followed by a 78-week open-label extension
Trial is registered as NCT07699471 on clinicaltrials.gov
Artelo Biosciences filed a Certificate of Change in Nevada on August 26, 2026, to carry out a 1-for-9 reverse stock split of its common stock. The split takes effect at 5:00 p.m. Eastern Time on August 28, 2026, and the company said it is intended to improve the stock's marketability and liquidity. Each holder's pro-rata ownership is stated to remain unchanged, though the share count falls and the new CUSIP changes.
Each nine pre-split shares combine into one new share; outstanding shares fall from 4,929,966 to approximately 547,774.
Authorized common shares are reduced from 500,000,000 to 55,555,556.
Shares are expected to begin trading on a split-adjusted basis on Nasdaq on August 31, 2026, under new CUSIP 04301G805.
No fractional shares will be issued; holders entitled to a fraction receive one whole share.
ABVC BioPharma completed the separation of its subsidiary BioKey Cayman, distributing about 15% of BioKey Cayman's ordinary shares to ABVC common stockholders as a pro rata dividend effective August 21, 2026. ABVC retains about 85% ownership and control, and BioKey Cayman is no longer a wholly owned subsidiary, but no trading market for its shares exists yet and it intends to seek OTC Markets quotation.
Distribution of 4,500,390 BioKey Cayman ordinary shares, at 0.169464 share per ABVC common share held at the close of business on July 24, 2026
Distribution effective 11:59 p.m. New York City time on August 21, 2026; ABVC holds approximately 85% of BioKey Cayman
No trading market exists yet; BioKey Cayman plans to seek OTC Markets quotation and has no trading symbol
HealthEquity reported second-quarter results for the period ended July 31, 2026, with revenue up 8%, net income up 10% and GAAP diluted earnings per share of $0.78, compared with $0.68 a year earlier. The company also raised its fiscal 2027 guidance, now expecting revenue of $1.411 billion to $1.421 billion and GAAP net income of $2.88 to $2.96 per diluted share.
Q2 revenue rose 8% to $350.7 million; net income rose 10% to $65.6 million
Adjusted EBITDA rose 11% to $167.0 million, with margin at 48% versus 46% a year earlier
Fiscal 2027 outlook: revenue $1.411 billion to $1.421 billion; non-GAAP EPS $4.66 to $4.73
Repurchased $108.1 million of stock in the quarter; $948.4 million remained authorized as of July 31, 2026
Black Spade Acquisition III Co, a special purpose acquisition company listed on the NYSE, signed a business combination agreement with Astrum Space Inc, a satellite communications company developing a satellite-to-device broadcast network for Asia-Pacific. The deal would merge Astrum into the listed shell, which would be renamed Astrum Space Company, and the combined company is expected to close by the end of 2026, subject to shareholder and regulatory approvals. The deal values Astrum at about $1 billion in equity value, and shareholder redemptions could reduce the cash available from the trust account.
Astrum equity value is approximately $1 billion, excluding about $172.5 million of cash in BIII's trust account, assuming no redemptions.
Existing Astrum shareholders would hold over 80% of the combined company if no BIII shareholders redeem their shares for cash.
Astrum's founder has committed to provide up to $168 million in funding to the Astrum group under a letter of support dated August 21, 2026.
Closing is expected by the end of 2026 and requires NYSE listing approval, BIII shareholder approval and an effective Form F-4 registration statement.
Perma-Pipe International Holdings entered into a new secured credit agreement with J.P. Morgan on August 25, 2026, replacing its existing credit agreement, which was terminated and repaid in full. The facility includes a $75.0 million revolver and a $14.0 million term loan, with up to $50.0 million of additional capacity available on request, and matures August 25, 2031. The filing describes the change as consolidating multiple facilities into one global arrangement, and it adds covenants on leverage and fixed charge coverage.
Facility: $75.0 million revolving credit line and $14.0 million term loan, maturing August 25, 2031
At closing, the company borrowed $14.0 million under the term loan and had $23.0 million outstanding under the revolver
Replaced the existing credit agreement, with proceeds and other cash used to repay its borrowings in full
Requires a leverage ratio of no more than 3.00 to 1.00 and a fixed charge coverage ratio of at least 1.25 to 1.00
Velocity Commercial Capital, LLC, a subsidiary of Velocity Financial, signed an agreement on August 26, 2026 to buy the operating platform of Toorak Capital LLC for a base price of about $62 million plus estimated tangible book value. Toorak's roughly $3 billion loan portfolio is being sold separately to a third-party investment firm, which Velocity will then manage, and the transactions are expected to close in the fourth quarter of 2026. Velocity expects the deal to be accretive to GAAP earnings in 2027.
Base purchase price of about $62 million plus estimated tangible book value, subject to adjustments
Toorak's loan portfolio of about $3 billion in unpaid principal balance is being sold to a third-party investment firm, which Velocity will manage
Closing expected in the fourth quarter of 2026; either party may terminate if the deal does not close within 120 days, subject to exceptions
Velocity's disinterested directors unanimously approved the transactions
Lucky Strike Entertainment reported fourth-quarter and fiscal 2026 results, with total revenue up 0.9% in the quarter and 3.7% for the year, but same-store revenue fell 2.5% in the quarter and 0.2% for the year. Adjusted EBITDA declined in both periods, and the full-year net loss widened to $35.8 million from $10.0 million, while the quarterly net loss narrowed to $26.2 million from $74.7 million. The company also issued fiscal 2027 guidance calling for total revenue of $1,280 million to $1,310 million and adjusted EBITDA of $340 million to $360 million.
Q4 total revenue $303.9 million, up 0.9%; same-store revenue down 2.5%, which the company attributed largely to June, when the World Cup drew viewers away from its venues
Q4 net loss $26.2 million vs. $74.7 million a year earlier; adjusted EBITDA $74.1 million vs. $88.7 million
Fiscal 2026 net loss $35.8 million vs. $10.0 million; adjusted EBITDA $333.2 million vs. $367.7 million
Fiscal 2027 guidance: total revenue growth of 3% to 5%, adjusted EBITDA $340 million to $360 million, capital expenditures of about $90 million; quarterly dividend of $0.06 per share payable September 22, 2026
Karman Holdings Inc. said Chris Boynton, previously Executive Vice President and CFO of Battelle, will become Executive Vice President and CFO on September 14, 2026. Mike Willis, the current CFO, will step down from that role on the same date and leave the company by year-end after a phased transition. The company said the change follows succession planning as it grows after its February 2025 initial public offering, and the filing sets out the terms of Boynton's offer letter.
Boynton's offer letter sets an annual base salary of $750,000 and a one-time sign-on bonus of $500,000.
Target annual cash incentive is 100% of base salary, with a stretch target of 150%.
His initial 2026 long-term incentive grant is 37,860 shares, 70% performance stock units and 30% restricted stock units.
Severance is 100% of base salary plus target bonus over 12 months, or 18 months of base salary in a lump sum plus target bonus if terminated within 12 months after a change in control.
Titan Machinery reported fiscal second-quarter revenue of $496.4 million, down from $546.4 million a year earlier, and a net loss of $9.2 million, or $0.40 per diluted share, versus a $6.0 million loss, or $0.26 per share, last year. The company reaffirmed its fiscal 2027 profitability outlook but cut its Europe segment revenue assumption, so weaker sales and losses point to pressure on shareholder returns.
Gross profit margin rose to 18.6% from 17.1%, but gross profit slipped to $92.4 million from $93.6 million.
Adjusted EBITDA was $4.6 million, compared with $5.6 million a year earlier.
Europe fiscal 2027 revenue assumption was revised to down 30% to 40%, from down 20% to 25%; the company reaffirmed adjusted EBITDA of $17.0 million to $29.0 million.
Net cash used for operating activities was $25.1 million for the six months ended July 31, 2026, compared with $49.9 million provided a year earlier.
Core Scientific entered into a credit agreement on August 25, 2026, providing a $100 million revolving credit facility and a $500 million letter of credit facility, with no amounts outstanding at closing. The company said the facilities are expected to release about $300 million of restricted cash, which management says will improve capital efficiency and financial flexibility. The agreement is secured by substantially all company assets and carries covenants limiting debt, liens, dividends and share repurchases.
Credit agreement dated August 25, 2026, with JPMorgan Chase Bank, N.A. as administrative agent and collateral agent
$100 million revolving facility matures in three years, or four at the company's election; $500 million letter of credit facility
Revolver borrowings priced at Adjusted Term SOFR plus 1.75% or alternate base rate plus 0.75%; no amounts outstanding at closing
Company expects the facilities to release approximately $300 million of restricted cash, per CFO Jim Nygaard
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.